Page 64 - Stock Markets

An old, new bull market?

Rising inflation, rising interest rates, and slow growth together act as a cold wet blanket on the stock market

History revisited: Indices rebound after 3 consecutive months of declines

This follows 2020, 2012, 2011 pattern, and the one in 2008, during the Global Financial Crisis

The big bounce-back: Nifty logs biggest monthly gains since November 2020

FPIs buy shares worth Rs 6,300 crore, first net inflow since Sept 2021

Investors richer by over Rs 9 trn in three days of market rally

Among Sensex constituents, Tata Steel, Sun Pharma, Bajaj Finserv, IndusInd Bank, Infosys, Asian Paints, Reliance Industries and Bajaj Finance were the biggest gainer

Sun Pharma Q1 net profit soars 43% YoY to Rs 2,061 cr; revenue up 10%

It has reported an Ebitda (earnings before interest, tax, depreciation and ammortisation) of Rs 2,884 crore (including other operating revenues), with the Ebitda margin at 26.8 per cent.

Stock of this recently listed company has zoomed 50% in last six days

Post listing, institutional investors holdings in eMudhra increased by 3.28 percentage point to 14.99% as on June 30, 2022 from 11.71% as on May 27, 2022.

Markets surge after Fed signals slower rate hikes; Sensex up over 1,000 pts

Four-fifths of the Sensex constituents ended with gains. Bajaj Finance rose 10.7 per cent and was the best-performing index stock

Cipla Q1 revenue may be muted on high base, low Covid drug sales: Analysts

Cipla Q1 results preview: Analysts attribute the likely dull performance due to the high base of last year, and the reduction in revenue contribution from Covid-19 therapies in the recent quarter.

Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts

Sun Pharma Q1FY23 results: Prabhudas Lilladher foresees the company's net profit to rise 27 per cent year-on-year (YoY) to Rs 1,786 crores from Rs 1,445 crores in the year-ago quarter.

Markets advance ahead of US Fed decision; Sensex rises 548 points

However, gains were capped as investors remained in wait and watch mode

Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts

Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.

This Rakesh Jhunjhunwala-owned stock has surged 64% from July's record low

Star Healthcare rallied 10% to Rs 768 in intra-day today, and has rebounded 64% from its record low of Rs 469.05 touched on July 1, 2022.

Zomato slumps 11%, closes at new low of Rs 47.55 as one-yr IPO lock-in ends

Start-ups with no 'promoter' may face pressure

Street Signs: Stocks in overbought territory, PVR shares flat, and more

Markets are expected to remain volatile on opening as they absorb the results of Reliance Industries and Infosys

Markets gain for sixth consecutive day in longest streak since October

The rally in banking and finance stocks after some banks posted good quarterly results also helped sentiment

Sensex, Nifty gain 4% this week; here's what drove the rebound

While analysts feel the fundamental backdrop has not drastically changed, a combination of domestic and global factors have lowered investors' apprehension.

Bulls back on D-Street: Indices gains 4% in the past 5 trading sessions

IndusInd Bank was the best-performing Sensex stock and rose 7.8 per cent

Cummins India surges 25% in one month; nears record high on healthy outlook

Cummins India expects the current trend of sustained growth across multiple industries and segments, demand outlook from various end markets to be positive.

Markets surge amid 'peak inflation' optimism, gain now 4% in 4 days

Sensex closes at highest level since June 6; Up 8% from CY22 lows

SBI gains 17% in one month, surpasses LIC to become most valued PSU stock

In the past one month, SBI has rallied 17 per cent, as compared to a 5 per cent gain in the stock price of LIC.